Please note that the contents in this webpage are current as of the date of the announcement and the information including but not limited to the product availability, specification, prices, contacts, are subject to change without prior notice.
- Feb 14, 2023
- Fujifilm Announces the Start of a New Phase III Clinical Trial in Japan Targeting Patients with Meniscus Injuries
- Dec 26, 2022
- Fujifilm and Utilization of Carbon Dioxide Institute sign a joint research agreement to develop technology toward decarbonized society
- Oct 14, 2022
- FUJIFILM Toyama Chemical discontinues development of “Avigan® Tablet” anti-influenza drug as a treatment for COVID-19
- Jun 1, 2022
- Fujifilm Begins U.S. Clinical Phase 2a Study of FF-10832 in Combination with KEYTRUDA® (pembrolizumab, Merck & Co., Inc., Rahway, N.J., U.S.A.) for Patients with Advanced Solid Tumors
- Apr 13, 2022
- Fujifilm and National Center of Neurology and Psychiatry announce positive study results of Fujifilm’s AI technology predicting mild cognitive impairment conversion to Alzheimer’s disease
- Mar 11, 2022
- Fujifilm to terminate the enrollment of subjects in the phase III clinical trial of anti-influenza drug Avigan® Tablet in Japan, targeting COVID-19 patients